| Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere Insulin or usual antidiabetes treatment: a randomised trial. | |
| | |
MedLine Citation:
|
PMID: 21951325 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Aims: Development of inhaled insulin has increased the need to understand its pulmonary safety. This study evaluated pulmonary function changes in diabetes patients receiving inhaled Technosphere Insulin (TI) or usual antidiabetes treatment (usual care). Materials and Methods: This randomised, open-label study was conducted at 220 sites (25 July 2005-29 August 2008). Pulmonary function tests (forced expiratory volume in 1 second [FEV(1) ], forced vital capacity [FVC], total lung capacity [TLC] and lung diffusion capacity for carbon monoxide [DL(CO) ]) were prospectively followed over 2 years in patients with type 1 or 2 diabetes receiving TI (n=730) or usual care (n=824), along with a cohort without diabetes not receiving any specific therapy (n=145). Results: Baseline demographics and pulmonary function were similar between diabetes treatment groups. Lung function declined from baseline in all groups. TI was non-inferior to usual care for mean change in FEV(1) from baseline to month 24 (mean [SEM] 0.037 [0.0119] L; 95% CI, 0.014 to 0.060) using mixed-model repeated-measure with a pre-specified non-inferiority margin of 50 mL/year. After a greater initial decline at month 3 with TI, rate of change (slope) in FEV(1) , FVC and DL(CO) (months 3-24) was not statistically different between treatment groups. TI was well tolerated; no serious safety concerns emerged. The most common respiratory event associated with TI was mild, transient cough, occurring within minutes of inhalation. Conclusions: Observed changes in lung function with TI were small, occurred early after therapy initiation, remained non-progressive over 2 years and were unlikely to be clinically meaningful. |
| | |
Authors:
|
P Raskin; S Heller; M Honka; P-C Chang; A H Boss; P C Richardson; N Amin |
Related Documents
:
|
10494895 - Urinary excretion of ceruloplasmin is elevated in the subjects with "borderline glucose... 8637455 - Effect of insulin on urinary phosphate excretion in type ii diabetes mellitus with or w... 7819935 - Role of glycaemic control in development of microalbuminuria in patients with insulin d... 9684785 - Distinct associations of hba1c and the urinary excretion of pentosidine, an advanced gl... 21303635 - Guidelines for optimal bolus calculator settings in adults. 21268025 - Phenylboronic acid grafted chitosan as a glucose-sensitive vehicle for controlled insul... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-9-23 |
Journal Detail:
|
Title: Diabetes, obesity & metabolism Volume: - ISSN: 1463-1326 ISO Abbreviation: - Publication Date: 2011 Sep |
Date Detail:
|
Created Date: 2011-9-28 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100883645 Medline TA: Diabetes Obes Metab Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
© 2011 Blackwell Publishing Ltd. |
Affiliation:
|
1University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA 2Sheffield Teaching Hospitals Foundation Trust, Sheffield, UK 3University Hospital Ostrava, Ostrava-Poruba, Czech Republic* 4MannKind Corporation, Valencia, CA, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Quality assurance and improvement: the Pediatric Regional Anesthesia Network.
Next Document: Overexpression of the immunoreceptor CD300f has a neuroprotective role in a model of acute brain inj...